February 16, 2017 / 9:31 PM / 6 months ago

BRIEF-Ultragenyx Q4 loss per share $1.75

Feb 16 (Reuters) - Ultragenyx Pharmaceutical Inc :

* Ultragenyx reports fourth quarter and full year 2016 financial results and corporate update

* Q4 loss per share $1.75

* Q4 earnings per share view $-1.72 -- Thomson Reuters I/B/E/S

* Ultragenyx Pharmaceutical Inc- ultragenyx plans to submit a biologics license application (bla) to U.S. FDA for krn23 in second half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below